Loading…
Legislative Progress
Introduced
February 28, 2005
Latest Action
February 28, 2005
Primary Sponsor
Christopher DoddDemocratic(CT)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,105 other S bills in the 109th — cohort avg 35d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (13)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 3428 OTC Medicine Tax Fairness Act of 2005 S. 1514 OTC Medicine Tax Fairness Act of 2005 H.R. 5280 Distribution Act of 2006 H.R. 6111 Tax Relief and health Care Act (Medicare) S.3678 Pandemic All Hazards Preparedness Act (Biodefense) S.103 Combat Meth Act of 2005 H.R. 314 Combat Meth Act of 2005 S.950 Elimination of Neglected Diseases Act of 2005 H.R. 3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006 H.R. 2744 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2006 Federal Food, Drug and Cosmetic Act (Section 767) H.R. 5762 Contact Lens Consumer Protection Act H.R. 5337 National Security Foreign Investment Reform and Strengthened Transparency Act of 2006 H.R. 2206 - Suplemental Appropriations H.R. 2207 - Agricultural Disaster Assistance and Western States Emergency Unfinished Business Appropriations Act of 2007 H.R. 1591 and S. 965 - US Troops Readiness, Veteran's Health, and Iraq Accountability Act of 2007 H.R. 3043 and S. 1710 - Department of Labor, Health and Human Services and Related Agenices Appropriations Act, 2008 H.R. 1908 and S. 1710 - Patent Reform Act of 2007 H.R 1 - Implementing the 9/11 Commission Recommendations Act of 2007 S. 1082 - Prescription Drug User Fee H.R. 2900 - Food and Drug Administration Amendments Act of 2007 H.R. 3282 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 H.R. 3162 - Children's Health and Medicare Protection Act of 2007 Access to Life Saving Medicines Act Citizens Petition Access to Generics Public Health Service Act Drug Importation Medicare Part B and Part D Sickle Cell Anemia Immunosuppressant Legislation Gene Therapy Direct to Consumer Advertising Medicare Prescription Drugs and Modernization Act Follow-on Biologics Patent Law Reform Authorized Generics Drug Safety Legislation DoD Authorization Language Global Hypertension Best Pharmaceuticals for Children's Act Pediatric Research Equity Act H.R. 970 and S. 1378 - Dextromethorphan Distribution Act of 2007 S. 930 - Food and Drug Administration Safety Act of 2005 H.R. 2090 - Food and Drug Administration Improvement Act of 2005 S. 470 FACT Act
Client expense: $2,700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2006 · mid_year · Consumer Issues/Safety/Products
HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety S 930, Food and Drug Administration Safety Act of 2005, drug safety HR 5156, Counterfeiting Drug Prevention Act, pharmaceutical counterfeiting HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety HR 3196, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
Client expense: $6,000,000 · Firm income: Not reported
2006 · year_end · Consumer Issues/Safety/Products
HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety S 930, Food and Drug Administration Safety Act of 2005, drug safety HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 3834, Online Pharmacy Consumer Protection Act of 2006, drug safety HR 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 4157, Better Health Information System Act, health information technology HR 5975, Prescription Drug Effectiveness Act, drug prescriptions S 2699, Neglected Diseases Elimination Act, promote R&D HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety HR 3196, The Fair Access to Clinical Trials ("RACT") Act of 2005, drug safety HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
Client expense: $5,800,000 · Firm income: Not reported
H.R. 3428 OTC Medicine Tax Fairness Act of 2005 S. 1514 OTC Medicine Tax Fairness Act of 2005 S. 3807 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lenses as medical devices,and for other purposes H.R. 371 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contaact lenses as medical devices, and for other purposes H.R. 5280 Distribution Act of 2006 H.R. 6111 Tax Relief and health Care Act (Medicare) S.3678 Pandemic All Hazards Preparedness Act (Biodefense) S.103 Combat Meth Act of 2005 H.R. 314 Combat Meth Act of 2005 S.950 Elimination of Neglected Diseases Act of 2005 H.R. 3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006 H.R. 2744 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2006 Federal Food, Drug and Cosmetic Act (Section 767) H.R. 5762 Contact Lens Consumer Protection Act H.R. 5337 National Security Foreign Investment Reform and Strengthened Transparency Act of 2006 Access to Life Saving Medicines Act Citizens Petition Access to Generics Public Health Service Act Drug Importation Medicare Part B and Part D Sickle Cell Anemia Immunosuppressant Legislation Cancer Therapies Legislation Gene Therapy Direct to Consumer Advertising Medicare Prescription Drugs and Modernization Act Follow-on Biologics Patent Law Reform Authorized Generics Drug Safety Legislation 1-800 Contacts DoD Authorization Language H.R. 2218 Regulation of non corrective contact lens as medical devises S. 930 Food and Drug Administration Safety Act of 2005 H.R. 2090 Food and Drug Administration Improvement Act of 2005 S. 470 FACT Act
Client expense: $1,860,000 · Firm income: Not reported
2006 · year_end · Pharmacy
e) S. 109, "Pharmaceutical Market Access Act of 2005". f) S. 334, "Pharmaceutical Market Access & Drug Safety Act of 2005". g) Issues related to clinical trial data bank. h) S. 470, H.R. 3196, "Fair Access to Clinical Trials Act". i) H.R. 6257, "Access to Life-Saving Medicines Act". a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.930, "Food & Drug Administration Act of 2005". c) H.R. 2090, "Food & Drug Administration Improvement Act of 2005". d) H.R. 700, "Pharmaceutical Market Access & Drug Safety Act of 2005" - Importation.
Client expense: $1,231,846 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
| Democratic |
| IL |
| Ron Wyden | Democratic | OR |
| Tim Johnson | Democratic | SD |
| Tom Harkin | Democratic | IA |
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2006 · year_end · Pharmacy
S 470, S 930, S 3807 - prescription drugs safety; generic drugs; best buy drugs; contact lens prescription non-discrimination; prescription drugs affordability' S 2342, HR 752 - Medicare Part D; FDA drugs safety
Client expense: $269,784 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Education, Dept of, Federal Communications Commission (FCC), Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Highway Traffic Safety Administration (NHTSA), Natl Telecommunications & Information Administration (NTIA), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE
2006 · year_end · Pharmacy
e) S. 109, "Pharmaceutical Market Access Act of 2005". f) S. 334, "Pharmaceutical Market Access & Drug Safety Act of 2005". g) Issues related to clinical trial data bank. h) S. 470, H.R. 3196, "Fair Access to Clinical Trials Act". i) H.R. 6257, "Access to Life-Saving Medicines Act". a) Issues related to Drug Safety, Generic Biologics & Drug Approvals, FDA User Fees. b) S.930, "Food & Drug Administration Act of 2005". c) H.R. 2090, "Food & Drug Administration Improvement Act of 2005". d) H.R. 700, "Pharmaceutical Market Access & Drug Safety Act of 2005" - Importation.
Client expense: $1,231,846 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2006 · year_end · Consumer Issues/Safety/Products
HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety S 930, Food and Drug Administration Safety Act of 2005, drug safety HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 3834, Online Pharmacy Consumer Protection Act of 2006, drug safety HR 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 4157, Better Health Information System Act, health information technology HR 5975, Prescription Drug Effectiveness Act, drug prescriptions S 2699, Neglected Diseases Elimination Act, promote R&D HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety HR 3196, The Fair Access to Clinical Trials ("RACT") Act of 2005, drug safety HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
Client expense: $7,720,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2006 · year_end · Health Issues
Ryan White Reauthorization Act HR 575 - Say No to Drug Ads Act HR 810 - Stem Cell HR 870 - PhRMA Act of 2005 HR 1457 - Health Information Technology Act of 2005 HR 2090 - Food and Drug Administration Improvement Act of 2005 HR 3196, S 470 - Fair Access to Clinical Trails Act HR 3204 - Public Health Service Act HR 3696 - Medical Advertising Reform Act HR 4157, S 1418 - Health Information Technology S 1955 - Small Business Health Plans S 3546 - Dietary Supplement and Non-Prescription Drug Consumer Protection Act S 3807 - Enhancing Drug Safety and Innovation Act of 2006 S 3897 - Medicare Access & Data S 4098 - Pediatric Medical Device Safety and Improvement Act of 2006 FDA Regulation of Single-Use Device Re-Processing Hospital Group Purchasing Organizations Pediatric Medical Devices Pharmaceutical Reimportation
Client expense: $2,080,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2006 · year_end · Health Issues
Fair Access to Clinical Trials Act (S470/HR3196); FDA Improvement Act (S930/HR2090); Wired for Health Care Quality Act (S1418); Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700); Labor-HHS Appropriations; AHRQ Comparative Effectiveness Research (HR 5975); Reauthorization of PDUFA; Health Information Technology (HR 4157/S 1418) FDA reform regarding oversight of drug safety.
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2006 · year_end · Medicare/Medicaid
S 1932/HR 4241-Deficit Reduction Act of 2005 (Bills concerned with gainsharing and its implications on patient access to medical devices efficiency standards in pay-for-performance program) HR 5369-Medicare Clinical Laboratory Fee Schedule Improvement Act of 2006 (Bill to improve payments under the Medical clinical laboratory fee schedule) S. 3900-Medicare Quality Enhancement Act of 2006 (Bill to improve quality and efficiency of health care, to provide public with information on provider and supplier performance, and to enhance education and awareness of consumers for evaluating health care services through development and release of reports based on Medicare enrollments, claims, survey, and assessment data) HR 5866-Medicare Physician Payment Reform and Quality Improvement Act of 2006 (Bill to reform physician payment under the Medicare program) HR 3617-Medicare Value-Based Purchasing for Physicians’ Services Act of 2005 (Bill to provide for value-based purchasing in the payment for physicians’ services under the Medicare program) S 1356-Medicare Value Purchasing Act of 2005 (Bill to provide incentives for the provision of high quality care under the Medicare program) S 1002-Hospital Fair Competition Act of 2005 (Bill to make improvements in payments to hospitals under the Medicare program) HR 4297-Tax Relief Extension Reconciliation Act of 2005 S 2020-Tax Relief Act of 2005 (Bills to provide for reconciliation pursuant to section 202(b) of the concurrent resolution on the budget for fiscal year 2006) HR 6063-The Remote Monitoring Access Act of 2006 S 2022-Remote Monitoring Access Act of 2005 (Bills to provide for coverage of remote patient management services for chronic health care conditions under the Medicare program) S 3795/HR 5704-Access to Medicare Imaging Act of 2006 (Bills to provide for a budget-neutral two-year moratorium on certain Medicare physician payment reductions for imaging services) HR 3559-Medicare Durable Medical Equipment Access Act of 2005 (Bill to assure access to durable medical equipment under the Medicare Program) HR 4994-Medicare Access to Complex Rehabilitation and Assistive Technology Act of 2006 (Bill to exempt complex rehabilitation products and assistive technology products from the Medicare competitive acquisition program) S 3920-Medicare Durable Medicare Equipment Access Act of 2006 (Bill to assure access to durable medical equipment under the Medicare Program) HR 3196/S 470-Fair Access to Clinical Trials (FACT) Act (Bills to expand the scope of information required for the data bank on clinical trials) S 3822-Genomics and Personalized Medicine Act of 2006 (Bill to improve access and appropriate utilization of valid, reliable and accurate molecular genetic tests by all populations)
Client expense: $1,404,102 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2006 · year_end · Medical/Disease Research/Clinical Labs
H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, Lobbied for final passage of the bill. H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs.
Client expense: $2,980,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2006 · year_end · Health Issues
H.R. 4157, Health Information Technology Promotion Act of 2006. S. 1418, Wired for Health Care Quality Act. H.R. 1227, The Genetic Information non-discrimination Act. H.R. 3196 & S. 470, Fair Access to Clinical Trials (FACT). S. 285 & H.R. 1246, The Children's Hospitals Education Equity and Research Act. Support medical liability reforms. S. 544 Medical Errors/patient safety legislation-monitor and track. The genetic information non-discrimination legislation. Pediatric Research. Clinical research issues. Asthma Legislation. H.R. 2098, the "Asthma Act." S. 1489, the Family Asthma Act. H.R. 5574, Children's Hospital GME Support Reauthorization Act. FDA Drug Safety Issues. FDA Conflict of Interest Issues.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2006 · mid_year · Medical/Disease Research/Clinical Labs
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, lobbied for final passage of the bill.
Client expense: $2,760,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2005 · year_end · Health Issues
Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700) "Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2005 · year_end · Health Issues
Clinical trials; Katrina public health; S.544 & HR 3205 Patient safety; S.470 Fact Act; S.1418 Health Information Technology; S.930 Food and Drug Administration Safety Act
Client expense: $278,948 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Consumer Product Safety Commission (CPSC), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of the Comptroller of the Currency (OCC), SENATE, State, Dept of (DOS)
2005 · year_end · Medical/Disease Research/Clinical Labs
H.R. 810/S.471, Stem Cell Research Enhancement Act of 2005 S.658/H.R. 1357, Human Cloning Protection Act of 2005 S.1520, Human Cloning Ban Act of 2005 S.1373, Human Chimera Prohibition Act of 2005 S.470, Fair Access to Clinical Trials (FACT) Act of 2005
Client expense: $600,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Natl Aeronautics & Space Administration (NASA), SENATE, State, Dept of (DOS), White House Office
2005 · year_end · Medical/Disease Research/Clinical Labs
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
Client expense: $2,580,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2005 · year_end · Medical/Disease Research/Clinical Labs
S. 950: Elimination of Neglected Diseases (END) Act of 2005 S. 492: Safe Water: Currency for Peace Act of 2005 S. 850: The Global Health Corps Act S. 2170: The Global Pathogens Surveillance Act of 2005 S. 1698: Vaccines for the New Millennium Act of 2005 S. 470: Fair Access to Clinical Trials Act of 2005 H.R. 3196: Fair Access to Clinical Trials Act
Client expense: Not reported · Firm income: $20,000
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2005 · year_end · Health Issues
S. 16: A bill to reduce to the cost of quality health care coverage and improve the availability of health care coverage for all Americans. Lobbied to protect the interests of the Biotech drug industry. S. 109, H.R. 328: A bill entitled the "Pharmaceutical Market Access Act of 2005". Lobbied for an exemption for biologics.S.184,H.R. 753: A bill to amend the Federal Food, Drug, and Cosmetic Act to protect the public health from the unsafe importation of prescription drugs and from counterfeit prescription drugs, and for other purposes. Lobbied for an exemption for biologics. S. 334, H.R. 700: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 563: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate and disclose lowest possible prices for prescription drug prices for Medicare beneficiaries, and with respect to the Federal Food, Drug, and Cosmetic Act, to provide waivers that permit such beneficiaries to import prescription drugs from Canada. Lobbied for an exemption for biologics. H.R. 578: To amend the Internal Revenue Code of 1986 with respect to the purchase of prescription drugs by individuals who have attained retirement age, and to amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs and the sale of such drugs through Internet sites. Lobbied for an exemption for biologics. H.R.1626: To amend part D of the title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negptiate for lower prices for Medicare prescription drugs and to eliminate the gap in coverage of Medicare prescrition durg benefits, to the Secretary of Health and Human Services to promulgate regulations for the reimportation of prescription drugs, and for other purposes. Lobbied for an exemption for biologics. H.R. 2599: To improve the quality, availability, diversity, personal privacy, and innovation of health care in the United States. Lobbied for an exemption for biologics.. H.R.16: To authorize the use of Federal funds for research on human embryonic stem cells irrrespective of the date on which such stem cells were derived, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 596, S. 681: To amend the Public Health Service Act to establish a National Cord Blood Stem Cell Bank Network to prepare, store, and distribute human umbilical cord blood stem cells for the treatment of patients and to support peer-reviewed research using such cells. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 810, S. 471: To amend the Public Health Service Act to provide for human embryonic stem cell research. H.R.1650: To amend the Internal Revenue Code of 1986 to allow tax credits to holders of stem cell research bonds. Lobbied to prevent the unreasonable restriciton of legitimate medical research or clinical trials. H.R. 1822, S. 876: To prohibit human cloning and protect stem cells research. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2541: To amend the Public Health Service Act to provide for the expansion, intensification, and coordination of the activities of the National Institutes of Health regarding qualifying adult stem cell research, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R.2520, S.1317: To provide for the collection and maintenance of human cord blood stem cells for the treatment of patients and research, and to amend the Public Health Service Act to authorize the C.W. Bill Young Cell Transplantation Program. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. H.R. 2574: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research on animals to develop techniques for the derivation of stem cells from embryos that do not harm the embryos, and for other purposes. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.1392: A bill to reauthorize the Federal Trade Commission. (Dorgan/Snowe Drug Importation Amendment). Lobbied for an exemption for biologics. H.R.3144: To amend the Public Health Service Act to provide for a program at the National Institutes of Health to conduct and support research in the derivation and use of human pluripotent stem cells by means that do not harm human embryos, and for other purposes. Lobbied for the interests of the vaccine industry. H.R.3423,S.1420: To amend the Federal Food, Drug, and Cosmetic Act with respect to medical device user fees. Lobbied for the interests of the medical device industry. S.226: A bill to amend the Public Health Service Act to improve immunization rates by increasing the supply of vaccines. Lobbied for the interst of the vaccine industry. S.521,H.R.1290: A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive prevention, research, and medical management referral program for hepatitis C virus infection. Supported bill. S.969,H.R.3369: A bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. Lobbied for the interests of the vaccine industry. S.1422,H.R.881: A bill to amend the Federal Food, Drug, and Cosmetic Act to reduce human exposure to mercury through vaccines. Lobbied for the interests of the vaccine industry. H.R.650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines, and for other purposes. Lobbied for the interests of the vaccine industry. H.R.1297: To amend the Public Health Service Act with respect to the National Vaccine Injury Compensation Program. Lobbied for the interests of the vaccine industry. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restricition of legitimate medical research or clinical trials. S.470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to provide the best information to the patient. H.R.2090: To amend the Federal Food, Drug, and Cosmetic Act to provide for the deposit in the general fund of the Treasury of fees that are collected from manufacturers of drugs and devices under chapter VII of such Act, to terminate the authority of the Food and Drug administration to negotiate with the manufacturers on particular uses of the fees, to establish a Center for Postmarket Drug Safety and Effectiveness, to establish additional authorities to ensure the safe and effective use of drugs, and for other purposes. Lobbied for provisions that promoted the development safe and effective drugs. H.R.2124,H.R.2308: To amend the Public Health Service Act to provide for clinical research support grants, clinical research infrastructure grants, and a demonstration program on partnerships in clinical research, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. H.R.2650: To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to protect consumers in managed care plans and other health coverage. Lobbied for the interests of the industry. H.R.2792: To permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests, and for other purposes. Lobbied for the interests of the industry. H.R.3196,H.R.2259,S.1012: To amend the Public Health Service Act to expand the scope of information required for the data bank on clinical trials of drugs, and for other purposes. Lobbied for reasonable provisions that support research and clinical trials. S.1128: A bill to amend title XIX of the Social Security Act to provide for increased rebates under the medicaid program for prescription drugs that are directly advertised to consumers, to require other Federal programs purchasing or reimbursing for such drugs to establish payment and reimbursement mechanisms that reduce the costs of those drugs, and for other purposes. Lobbied to ensure that any enacted restrictions would not impede access of the consumer to accurate information about pharmaceutical products. H.R.840,S.399: A bill to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.1808,S.334: To amend the Federal Food, Drug, and Cosmetic Act to create a uniform certification standard for Internet pharmacies and to prohibit Internet pharmacies from engaging in certain advertising activities, to prohibit the use of certain bank instruments for purchases associated with illegal Internet pharmacies, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.4395: To amend titles XVIII and XIX of the Social Security Act to provide for an improved voluntary Medicare prescription drug benefit, to provide greater access to affordable pharmaceuticals, and for other purposes. Lobbied for an exemption for biologics in the Drug Importation section. S.470: A bill to amend the Public Health Service Act to expand the clinical trials drug data bank. Lobbied to prevent the unreasonable restriction of legitimate medical research or clinical trials. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. Lobbied to prevent the unreasonable restricition of legitimate medical research or clinical trials. S.1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R.2345: To amend the Federal Food, Drug, and Cosmetic Act to increase criminal penalties for the sale or trade of prescription drugs knowingly caused to be adulterated or misbranded, to modify requirements for maintaining records of the chain-of-custody of prescription drugs, to establish recall authority regarding drugs, and for other purposes. Lobbied in support of enhanced FDA authorities over counterfeit products. H.R.3052,S.1527: Vaccine Access and Supply Act, lobbied for provisions to strengthen the domestic vaccine industry. H.R.3970: Bioterror and Pandemic Preparedness Protection Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1821: Pandemic Preparedness and Response Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1828: Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure as strong domestic vaccine industry. S.1912: Global Network for Avian Influenza Surveillance Act, lobbied in support of domestic pandemic preparedness. S.375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stabilize production and supply. S.969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions. General matters related to vaccine industry stability, pandemic preparedness, avian influenza.
Client expense: Not reported · Firm income: $100,000
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2005 · mid_year · Medical/Disease Research/Clinical Labs
HR 810/S. 471 “The Stem Cell Research Enhancement Act of 2005” communicated with and met in person with House and Senate staff regarding the scientific and ethical implications of both embryonic and adult stem cell research; requested that members of the Maryland delegation co-sponsor the legislation; participated in advocacy activities in conjunction with the Coalition for the Advancement of Medical Research (CAMR), the Association of American Universities (AAU) and Association of American Medical Colleges (AAMC) towards the passage of the House bill and a strategy for passage in the Senate; Also monitored other stem cell related legislation , including that addressing: human cloning (S. 658/HR 1357) and regulation of so-called chimeras. Also monitored: S. 470 ‘Fair Access to Clinical Trials (FACT) Act of 2005) Responded to inquiries from the Maryland House delegation re. the participation of foster children in federally sponsored HIV/AIDS research protocols. Monitored issues involved with federal effort reporting requirements in conjunction with the Association of American Univiersities (AAU), the Amercian Association of Medical Colleges (AAMC), and the Council on Government Relations (COGR). In conjuction with efforts undertaken by the Association of American Medical Colleges (AAMC), prepared and submitted unsolicited comments related to new conflict of interest rules proposed by the Department of Health and Human Services with respect to employees of the National Institutes of Health
Client expense: $420,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Natl Aeronautics & Space Administration (NASA), SENATE, State, Dept of (DOS)
2005 · mid_year · Health Issues
H.R.3423/S.1420-Medical Device User Fee Stabilization Act of 2005. (Bills related to user fees for medical devices.) H.R. 2090-Food and Drug Administration Improvement Act of 2005 (Bill related to FDA Advisory panels.) H.R.3196/S.470-Fair Access to Clinical Trials (FACT) Act (Bills to expand the scope of information required for the data bank on clinical trials.) S.3-Protecting America in the War on Terror Act of 2005 - Biopreparedness Act of 2005. (Bill sets provisions concerning bioterrorism preparedness and defense as pertaining to medical devices.) S.975-The Project Bioshield II Act of 2005. (Bill to provide incentives to increase research by private sector entities to develop medical countermeasures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak.) H.R.5-Help, Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2005. (Bill to provide improved medical care by reducing excessive burden the liability system places on the health care delivery system.) S.295-To authorize appropriate action if the negotiations with the People's Republic of Chhina's undervalued currency are not successful. (Bill to impose an additional duty of 27.5% on Chinese imports.) H.R.3004-Currency Harmonization Initiative through Neutralizing Action Act of 2005. (Bill to impose additional tariffs on Chinese imports on the basis of the rate of manipulation by that country of the rate of exchange between the Chinese currency and the U.S. dollar.) H.R.3045/S.1307-Dominican Republic-Central American-United States Free Trade Agreement Implementation Act. (Bills implementing the Central American-Dominican Republic Free Trade Agreenment (CAFTA-DR) into law.) H.R.3283/S.1421-United States Trade Rights Amendments Act (Bill to enhance resources to enforce U.S. trade rights.) S.950-Elimination of Neglected Diseases Act of 2005. (Bill to provide assistance to combat turburculosis, malaria and other infecitous diseases.) S.1223-Information Technology for Health Care Quality and Improvement Act. S.1355-Better Healthcare Through Information Technoogy. (Bills to enhance the adoption of health information technology and to improve the quality and reduce the costs of health care in the United States.) S.1262-Health Technology to Enhance Quality Act of 2005. S.1418-Wired for Health Care Quality Act (Bills to reduce healthcare costs, improve efficiency and healthcare quality through development of a nation-wide interoperable health information technology system.) S.978-Healthcare Tax Relief for the Uninsured Act of 2005. H.R.1872-Health Coverage for the Uninsured Act of 2005. (Bills to provide tax incentives for the purchase of quality health care, and for other purposes.)
Client expense: $2,460,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)
H.R.2218 Regulation of non corrective contact lens as medical devices S.930 Food and Drug Administration Safety Act of 2005 H.R.2090 Food and Drug Administration Improvement Act of 2005 H.R.3196 - Fair Access to Clinical Trials Act S. 470 - FACT Act H.R.3428 - OTC Medicine Tax Fairness Act of 2005 S.1514 - OTC Medicine Tax Fairness Act of 2005 S.172 - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of all contact lenses as medical devices, and for other purposes. H.R.371 - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of all contact lenses as medical devices, and for other purposes. S.103 - Combat Meth Act of 2005 H.R.314 - Combat Meth Act of 2005 S.950 Elimination of Neglected Diseases Act of 2005 H.R.3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006 Drug Importation Medicare Part B and Part D Sickle Cell Anemia Immunosuppressant Legislation Cancer Therapies Legislation Gene Therapy Direct to Consumer Advertising Medicare Prescription Drugs & Modernization Act
Client expense: $1,841,931 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2005 · mid_year · Health Issues
Department of Defense peer-reviewed Breast Cancer Research Program (BCRP) for fiscal year 2006. Sent letter to Defense Appropriations Conferees supporting this program. Meetings with key congressional staff regarding program. Enactment of S.757/H.R.2231, the Breast Cancer and Environmental Research Act. Meetings with key congressional staff regarding cosponsorship. Phoned Members of Congress urging cosponsorship. Enactment of S.470, the Fair Access to Clinical Trials Act. Meetings and calls with key congressional staff regarding cosponsorship. Preventing cuts to Medicaid. Conducted meetings and calls, and wrote letters to Congress urging them to oppose cuts to Medicaid.
Client expense: $191,220 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), President of the U.S., SENATE, White House Office
2005 · mid_year · Medical/Disease Research/Clinical Labs
Department of Defense peer-reviewed Breast Cancer Research Program (BCRP) for fiscal year 2006. Sent letter to Defense Appropriations Conferees supporting this program. Meetings with key congressional staff regarding program. Enactment of S.757/H.R.2231, the Breast Cancer and Environmental Research Act. Meetings with key congressional staff regarding cosponsorship. Phoned Members of Congress urging cosponsorship. Enactment of S.470, the Fair Access to Clinical Trials Act. Meetings and calls with key congressional staff regarding cosponsorship. Preventing cuts to Medicaid. Conducted meetings and calls, and wrote letters to Congress urging them to oppose cuts to Medicaid.
Client expense: $191,220 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), President of the U.S., SENATE, White House Office
2005 · mid_year · Health Issues
Department of Defense peer-reviewed Breast Cancer Research Program (BCRP) for fiscal year 2006. Sent letter to Defense Appropriations Conferees supporting this program. Meetings with key congressional staff regarding program. Enactment of S.757/H.R.2231, the Breast Cancer and Environmental Research Act. Meetings with key congressional staff regarding cosponsorship. Phoned Members of Congress urging cosponsorship. Enactment of S.470, the Fair Access to Clinical Trials Act. Meetings and calls with key congressional staff regarding cosponsorship. Preventing cuts to Medicaid. Conducted meetings and calls, and wrote letters to Congress urging them to oppose cuts to Medicaid.
Client expense: $191,220 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), President of the U.S., SENATE, White House Office
2005 · mid_year · Medical/Disease Research/Clinical Labs
Department of Defense peer-reviewed Breast Cancer Research Program (BCRP) for fiscal year 2006. Sent letter to Defense Appropriations Conferees supporting this program. Meetings with key congressional staff regarding program. Enactment of S.757/H.R.2231, the Breast Cancer and Environmental Research Act. Meetings with key congressional staff regarding cosponsorship. Phoned Members of Congress urging cosponsorship. Enactment of S.470, the Fair Access to Clinical Trials Act. Meetings and calls with key congressional staff regarding cosponsorship. Preventing cuts to Medicaid. Conducted meetings and calls, and wrote letters to Congress urging them to oppose cuts to Medicaid.
Client expense: $191,220 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), President of the U.S., SENATE, White House Office
2005 · mid_year · Health Issues
S. 16: “Affordable Health Care Act” Legislation to reduce the cost of quality healthcare coverage and improve the availability of healthcare coverage for all Americans. S. 470, H.R. 3196: “Fair Access to Clinical Trials Act of 2005” Legislation to amend the Public Health Service Act to expand the clinical trials drug data bank. S. 810, H.R. 1653: “Safeguarding Americans From Exporting Identification Data Act” Legislation to prohibit the transfer of personal information to any person outside the United States, without notice and consent, and for other purposes. S. 930: “Food and Drug Administration Safety Act of 2005” Legislation to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. S. 1020: “Hospital Fair Competition Act of 2005” Legislation to amend title XVIII of the Social Security Act to make improvements in payments to hospitals under the Medicare program, and for other purposes – provisions related to gainsharing and DRG refinements. S. 1355: “Better Healthcare Through Information Technology Act” Legislation to enhance the adoption of health information technology and to improve the quality and reduce the costs of healthcare in the United States. H.R. 2234: “21st Century Health Information Act of 2005” Legislation to authorize the Secretary of Health and Human Services to make health information technology grants, and for other purposes. Communications regarding modifications to P.L. 107-250, The Medical Device User Fee and Modernization Act of 2002. Communications regarding FDA regulation of pediatric devices. Communications regarding physician pay-for-performance.
Client expense: Not reported · Firm income: $80,000
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)